Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM (2024) A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes
[1] In the United States, ALA is available as a dietary supplement and as a compounded injectable formulation (25 mg/mL in a 30 mL vial) prepared by compounding pharmacies and outsourcing facilities
Learn what your DNA reveals about GLP-1, GIP, and appetite-regulation pathways with the Precision Peptide Genetic Test, then bring that context to a qualified provider
video Kajy law firm gives car seats to families video Where do they stand
A 2023 review in Nature Reviews Endocrinology noted that while GLP-1 agonists can be safe short-term in non-diabetics, long-term effects are still unclear
Ongoing research on higher dosages of Rybelsus, reaching up to 50 mg, has shown results in weight reduction that are comparable with those of Wegovy (semaglutide), a medication specifically for weight loss
